Thanks Bear...always helpful so I downloaded Jan 9, 2017.

I'm trying to get my head around the Celgene x TRPH-395 economics/size of deal. I noted that Celgene has done a previous deal with Triphase regarding brain cancer drug marizomib. Perhaps this experience gives them the confidence that the Triphase epigenetic process is on the right track hence Celgene is comfortable with the $40 mUSD up front investment.

The tepid approach by Pfizer with 3694 vs Celgene x TRPH-395 seems huge and this has me scratching my head as to why. Perhaps Celgene takes a higher risk profile than Pfizer. Articles in the FP and Globe indicate a fundamental shift in BP strategies away from OTC to high margin perscription drugs, particularly in cancers. These articles are indicating some BP are looking to fill their pipelines as quickly as possible but this will take time. Therefore the Zenith strategy of extending the effectiveness of existing drugs should have significant value to companies as they build their pipelines.

Thanks also for the explanation of apples vs oranges. I'm definitely not the brightest like in the Xmas tree :) and I never would have understood the symbolism and it sure great that Zenith is there.

Toinv